Parameters | No. (%) | Mean ± SEM |
---|---|---|
Age (years) |  | 56.5 ± 0.8 |
Stage | Â | Â |
   I | 22 (11.7%) |  |
   II | 125 (66.5%) |  |
   III | 37 (19.7%) |  |
   IV | 4 (2.1%) |  |
Smoking | Â | Â |
   No | 173 (92.0%) |  |
   Yes | 15 (8.0%) |  |
Pelvic lymphadenopathy on CT scan | Â | Â |
   No | 167 (88.8%) |  |
   Yes | 21 (11.2%) |  |
Parametrial scores | Â | Â |
   0 | 36 (19.1%) |  |
   1-3 | 103 (54.8%) |  |
   4-6 | 49 (26.1%) |  |
Hemoglobin (g/dL) |  | 11.1 ± 0.2 |
Field size (Y-axis) (cm) |  | 18.3 ± 0.1 |
HDR dose to point A (Gy) |  | 24.3 ± 0.2 |
RT duration (days) |  | 61.2 ± 1.1 |
Pretreatment SCC-Ag level (ng/mL) |  | 15.2 ± 2.3 |
   < 2 | 60 (31.9%) |  |
   2-10 | 68 (36.2%) |  |
   10-20 | 21 (11.6%) |  |
   20-40 | 21 (11.6%) |  |
   ≥ 40 | 18 (9.6%) |  |
Pretreatment CEA level (ng/mL) |  | 7.7 ± 1.7 |
   < 5 | 149 (79.3%) |  |
   5-10 | 16 (8.5%) |  |
   ≥ 10 | 23 (12.2%) |  |
EBRT technique | Â | Â |
   AP/PA | 2 (1.1%) |  |
   Four-field | 174 (92.6%) |  |
   IMRT | 12 (6.4%) |  |
EBRT dose (Gy) | Â | Â |
   Central dose |  | 42.2 ± 0.3 |
   Parametrial dose |  | 47.2 ± 0.4 |